Search

Your search keyword '"Nitescu, M"' showing total 18 results
Start Over Author "Nitescu, M" Search Limiters Full Text
18 results on '"Nitescu, M"'

1. Parameter Identification for a New Circuit Model Aimed to Predict Body Water Volume

Author

GHEORGHE, A.-G., MARIN, C.-V., CONSTANTINESCU, F., and NITESCU, M.

Subjects
bioimpedance, circuit synthesis, frequency response, impedance measurement, passive circuits, Electrical engineering. Electronics. Nuclear engineering, TK1-9971, Computer engineering. Computer hardware, TK7885-7895
Abstract

Intracellular and extracellular water volumes in the human body have been computed using a sequence of models starting with a linear first order RC circuit (Cole model) and finishing with the De Lorenzo model. This last model employs a fractional order impedance whose parameters are identified using the frequency characteristics of the impedance module and phase, the latter being not unique. While the Cole model has a two octaves frequency validity range, the De Lorenzo model can be used for three decades. A new linear RC model, valid for a three decades frequency range, is proposed. This circuit can be viewed as an extension of the Cole model for a larger frequency interval, unlike similar models proposed by the same authors.

Published
2012
Full Text
View/download PDF

2. Parameter Identification for Nonlinear Circuit Models of Power BAW Resonator

Author

CONSTANTINESCU, F., GHEORGHE, A. G., NITESCU, M., FLOREA, A., LLOPIS, O., and TARAS, P.

Subjects
BAW resonators and filters, radiofrequency microelectromechanical systems, radio tranceivers, radiofrequency integrated circuits, circuits for communications, Electrical engineering. Electronics. Nuclear engineering, TK1-9971, Computer engineering. Computer hardware, TK7885-7895
Abstract

The large signal operation of the bulk acoustic wave (BAW) resonators is characterized by the amplitude-frequency effect and the intermodulation effect. The measurement of these effects, together with that of the small signal frequency characteristic, are used in this paper for the parameter identification of the nonlinear circuit models developed previously by authors. As the resonator has been connected to the measurement bench by wire bonding, the parasitic elements of this connection have been taken into account, being estimated solving some electrical and magnetic field problems.

Published
2011
Full Text
View/download PDF

5. Medical nutrition therapy in non-alcoholic fatty liver disease – a review of literature

Author

Rusu, E, Enache, G, Jinga, M, Dragut, R, Nan, R, Popescu, H, Parpala, C, Homentcovschi, C, Nitescu, M, Stoian, M, Costache, A, Posea, M, Rusu, F, Jinga, V, Mischianu, D, and Radulian, G

Subjects
Dietary Fiber, nutritional and metabolic diseases, Reviews, steatohepatitis, digestive system, digestive system diseases, Non-alcoholic Fatty Liver Disease, lifestyle changes, Dietary Carbohydrates, Humans, caloric restriction, Dietary Proteins, Nutrition Therapy, diet, Energy Intake, management
Abstract

Background and aim: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide, with a prevalence of 20%-40% in Western populations. The purpose of this article is to review data related to lifestyle changes in patients with NAFLD. Method: We searched a public domain database (PubMed) with the following categories: disease (NAFLD, fatty liver, and non-alcoholic steatohepatitis [NASH]) and intervention (lifestyle intervention, diet, nutrition) with each possible combination through 25 September 2014, for relevant articles. Review of articles was restricted to those published in English. We selected the studies involving adult patients only. Conclusion: There is no consensus as to what diet or lifestyle approach is the best for NAFLD patients. However, patients with NAFLD may benefit from a moderate- to low-carbohydrate (40%–45% of total calories) diet, coupled with increased dietary MUFA and n-3 PUFAs, reduced SFAs. More CRT are needed to clarify the specific effects of different diets and dietary components on the health of NAFLD patients. Abbreviations: NAFL = Non-alcoholic fatty liver, NAFLD = non-alcoholic fatty liver disease, NASH = non-alcoholic steatohepatitis, HCC = hepatocarcinoma, BEE = basal energy expenditure, CRT = A small clinical randomized trial showed that short-term carbohydrate restriction is more efficacious in reducing intrahepatic triglyceride, IHT = intrahepatic triglyceride, VLCD = Very low calorie diets, AST = aspartate aminotransferases, SFAs = saturated fatty acids.

Published
2015

6. Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season

Author

Rondy, M., Gherasim, A., Casado, I., Launay, O., Rizzo, C., Pitigoi, D., Mickiene, A., Marbus, S. D., Machado, A., Syrjanen, R. K., Pem-Novose, I., Horvath, J. K., Larrauri, A., Castilla, J., Vanhems, P., Alfonsi, V., Ivanciuc, A. E., Kuliese, M., Van Gageldonk-Lafeber, R., Gomez, V., Ikonen, N., Lovric, Z., Ferenczi, A., Moren, A., Pozo, F., Garcia, M., Latorre, M., Omenaca, M., Oribe Amores, M., Munoz, N., Cilla, G., Fernandino, L., Martinez-Baz, I., Navascues, A., Perez-Garcia, A., Aguinaga, A., Ezpeleta, C., Bella, A., Appelgren, E. C., Castrucci, M. R., Puzelli, S., Chironna, M., Germinario, C., Ansaldi, F., Manini, I., Montomoli, E., Lupulescu, E., Lazar, M., Mihai, M. E., Cherciu, C. M., Dinu, S., Tecu, C., Nitescu, M., Bacruban, R., Azamfire, D., Dumitrescu, A., Ianosik, E., Ceausu, E., Popescu, C. P., Florescu, S. A., Tardei, G., Bejan, C., Teodor, A., Juganariu, G., Plesca, C., Duca, E., Lenzi, N., Lesieur, Z., Loulergue, P., Galtier, F., Agostini, C., Ray, M., Merle, C., Foulongne, V., Lina, B., Laine, F., De Guibert, S., Lagathu, G., Tattevin, P., Jouneau, S., Esvant, A., Le Gallou, T., Carrat, F., Mawuvi, G., Chau, F., Nohynek, H., Haveri, A., Gefenaite, G., Velyvyte, D., Jancoriene, L., Zablockiene, B., Ambrozaitis, A., Grimalauskaite, R., Damuleviciene, G., Lesauskaite, V., Bagdonas, A., Nunes, B., Kislaya, I., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Bernard, K., Kurecic-Filipovic, S., Visekruna Vucina, V., Topic, A., Papic, N., Budimir, J., Oroszi, B., Meijer, A., Van Der Hoek, W., Schneeberger, P. M., EpiConcept [Paris], Institute of Health 'Carlos III', CIBER de Epidemiología y Salud Pública (CIBERESP), IDISNA, Pamplona, CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Istituto Superiore di Sanità (ISS), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Lithuanian University of health Sciences, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), National Institute for Health and Welfare [Helsinki], Croatian Institute of Public Health [Zagreb] (CIPH), Office of the Chief Medical Officer, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Laboratoire des pathogènes émergents -- Emerging Pathogens Laboratory (LPE-Fondation Mérieux), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institute of Biology Bucharest of Romanian Academy, Epidemiology Department, Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Istituto Superiore di Sanità Rome, Rome, Italy, Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), EpiConcept, Unión Europea, CIC Cochin Pasteur ( CIC 1417 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), F-CRIN, I-REIVAC, Institut National de la Santé et de la Recherche Médicale ( INSERM ), National Center for Epidemiology Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], 'Carol Davila' University of Medicine and Pharmacy, National Institute for Public Health and the Environment [Bilthoven] ( RIVM ), Instituto Nacional de Saúde Doutor Ricardo Jorge, Croatian Institute of Public Health, Zagreb, Hospices Civils de Lyon ( HCL ), Centre International de Recherche en Infectiologie ( CIRI ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-École normale supérieure - Lyon ( ENS Lyon ), Istituto Superiore de Sanita, HAL-UPMC, Gestionnaire, École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, 0301 basic medicine, Pediatrics, Epidemiology, Efetividade da Vacina Antigripal, A(H3N2), Influenza, cases control, elderly, hospitalisation, vaccine effectiveness, Elderly, 0302 clinical medicine, vaccine, Outcome Assessment, Health Care, Influenza A Virus, Hospitalisation, awareness, 030212 general & internal medicine, media_common, Vaccine effectiveness, virus diseases, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Middle Aged, Hospitals, 3. Good health, Hospitalization, Influenza Vaccines, H3N2 Subtype, Female, Seasons, influenza, Rapid Communication, Human, Adult, medicine.medical_specialty, Adolescent, Influenza vaccine, 030106 microbiology, Outcome Assessment (Health Care), 03 medical and health sciences, [SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology, Virology, Influenza, Human, medicine, Aged, European Union, Humans, Influenza A Virus, H3N2 Subtype, media_common.cataloged_instance, Vacina Antigripal, European union, Cases control, Cases Control, business.industry, Public health, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Case-control study, Influenza a, Confidence interval, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Emergency medicine, [ SDV.IMM.VAC ] Life Sciences [q-bio]/Immunology/Vaccinology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, Prevention control, business
Abstract

Members of the I-Move+hospital working group - Portugal: B. Nunes, I. Kislaya, A.P. Rodrigues (National Health Institute Doutor Ricardo Jorge, Lisbon), V. Gomes, R. Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon), J. Poças, M.J. Peres (Centro Hospitalar de Setúbal, Setúbal). In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate. Funding: The I-MOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). info:eu-repo/semantics/publishedVersion

Published
2017
Full Text
View/download PDF

7. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza

Author

Rondy, M., Launay, O., Castilla, J., Costanzo, S., Puig-Barbera, J., Gefenaite, G., Larrauri, A., Rizzo, C., Pitigoi, D., Syrjanen, R. K., Machado, A., Filipovic, S. K., Horvath, J. K., Paradowska-Stankiewicz, I., Marbus, S., Moren, A., Valenciano, M., Lenzi, N., Lesieur, Z., Loulergue, P., Galtier, F., Ray, M., Foulongne, V., Letois, F., Merle, C., Vanhems, P., Lina, B., Casado, I., Diaz-Gonzalez, J., Guevara, M., Martinez-Baz, I., Fernandino, L., Navascues, A., Ezpeleta, C., Chamorro, J., Barrado, L., Ortega, M. T., De Gaetano Donati, K., Cauda, R., Donato, C., Taccari, F., Campana, L., Santangelo, R., Perlasca, F., Fichera, G., Dara, M., Iacoviello, L., Olivieri, M., Alfonsi, V., Bella, A., Puzelli, S., Castrucci, M. R., Orsi, A., Ansaldi, F., Manini, I., Montomoli, E., Chironna, M., Germinario, C., Diez-Domingo, J., Sanudo, B., Carratala Munuera, C., Correcher Medina, P., Gil Guillen, V., Larrea Gonzalez, R., Limon Ramirez, R., Mico Esparza, J. L., Mollar Maseres, J., Otero Reigada, M. C., Tortajada Girbes, M., Schwarz Chavarri, G., Ambrozaitis, A., Jancoriene, L., Zablockiene, B., Zagminas, K., Aukse, M., Damuleviciene, G., Grimalauskaite, R., Kuliese, M., Lesauskaite, V., Velyvyte, D., Niesters, H., Stolk, R. P., Zagmines, K., Rahamat-Langendoen, J., Gherasim, A., Pozo, F., Altzibar, J., Arraras, J. G., Cilla, G., Marco, E., Vidal Garcia, M., Omenaca, M., Ivanciuc, A. E., Lupulescu, E., Lazar, M., Cherciu, C. M., Tecu, C., Mihai, M. E., Nitescu, M., Leca, D., Ceausu, E., Nohynek, H., Ikonen, N., Haveri, A., Gomez, V., Nunes, B., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Visekruna Vucina, V., Kaic, B., Novosel, I. P., Petrovic, G., Ferenczi, A., Oroszi, B., Korczynska, M. R., Brydak, L. B., Cieslik-Tarkota, R., Rozwadowska, B., Skolimowska, G., Hulboj, D., Jakubik, A., Meijer, A., Van Gageldonk-Lafeber, A. B., Research Council of Lithuania, and European Union

Subjects
0301 basic medicine, Male, Veterinary medicine, Immunology and Microbiology (all), medicine.disease_cause, Polymerase Chain Reaction, Aged, Aged, 80 and over, Case-Control Studies, Clinical Laboratory Techniques, Europe, Female, Hospitalization, Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus, Influenza Vaccines, Influenza, Human, Respiratory Tract Infections, Seasons, Sentinel Surveillance, Vaccination, Molecular Medicine, Veterinary (all), Public Health, Environmental and Occupational Health, Infectious Diseases, Seasonal influenza, IMOVE+, 0302 clinical medicine, 80 and over, Influenza A Virus, Influenza A virus, 030212 general & internal medicine, Respiratory tract infections, virus diseases, 3. Good health, H3N2 Subtype, Public Health, Human, medicine.medical_specialty, Influenza vaccine, 030106 microbiology, Virus, Hospital, 03 medical and health sciences, Repeated Vaccination, Internal medicine, medicine, H1N1 Subtype, Influenza Vaccine Effectiveness, General Veterinary, General Immunology and Microbiology, business.industry, Environmental and Occupational Health, Cuidados de Saúde, Case-control study, Influenza, Negative case, influenza vaccination, test negative case control, vaccine effectiveness, business
Abstract

In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015-16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: -35 to 64), 8% (95%CI: -94 to 56) and 33% (95%CI: -43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was -1% (95%CI: -80 to 43), 37% (95%CI: 7-57) and 43% (95%CI: 1-68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients' recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed. The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). The IMOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. GlaxoSmithKline, Sanofi Pasteur and Sanofi Pasteur MSD financially supported the InNHOVE network. They had no role in study design, data collection, pooled analysis, and publication. We are grateful to all patients, medical staff, study nurses and epidemiologists from the twelve study sites who actively participated in the study. info:eu-repo/semantics/publishedVersion

Published
2017

8. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project

Author

Rondy, Marc, Larrauri, A., Casado, I., Alfonsi, V., Pitigoi, D., Launay, O., Syrjänen, R. K., Gefenaite, G., Machado, A., Vučina, V. V., Horváth, J. K., Paradowska-Stankiewicz, I., Marbus, S. D., Gherasim, A., Díaz-González, J. A., Rizzo, C., Ivanciuc, A. E., Galtier, F., Ikonen, N., Mickiene, A., Gomez, V., Kurečić Filipović, S., Ferenczi, A., Korcinska, M. R., Van Gageldonk-Lafeber, R., Valenciano, M., Altzibar, Jone M., Arraras, Ion Garcia, Cilla, Gustavo, Marco, Elisa, Vidal, Matxalen, Omenaca, Manuel, Castilla, J., Navascues, A., Ezpeleta, C., Barrado, L., Ortega, M. T., Bella, A., Castrucci, M. R., Puzelli, S., Chironna, M., Germinario, C., Ansaldi, F., Orsi, A., Manini, I., Montomoli, E., Lupulescu, E., Lazar, M., Cherciu, C. M., Tecu, C., Mihai, M. E., Nitescu, M., Leca, D., Ceausu, E., Lenzi, N., Lesieur, Z., Loulergue, P., Foulongne, V., Letois, F., Merle, C., Vanhems, P., Lina, B., Nohynek, H., Haveri, A., Kuliese, M., Velyvyte, D., Grimalauskaite, R., Damuleviciene, G., Lesauskaite, V., Jancoriene, L., Zablockiene, B., Ambrozaitis, A., Nunes, B., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Kaić, B., Oroszi, B., Brydak, L. B., Cieślak, K., Kowalczyk, D., Szymański, K., Jakubik, A., Skolimowska, G., Hulboj, D., Meijer, A., Van Der Hoek, W., Schneeberger, P. M., Palmieri, Annapina, Giannitelli, Stefania, Ranghiasci, Alessia, Bacruban, Rodica, Azamfire, Delia, Dumitrescu, Aura, Ianosik, Elena, Duca, Elena, Bejan, Codrina, Teodor, Andra, Florescu, Simin-Aysel, Popescu, Corneliu, Tardei, Gratiela, Charpentier, Julien, Marin, Nathalie, Doumenc, Benoit, Le Jeunne, Claire, Krivine, Anne, Momcilovic, Sonia, Benet, Thomas, Amour, Selilah, Henaff, Laetitia, Jokinen, Jukka, Lyytikainen, Outi, Palmu, Arto, Siren, Paivi, Ruokokoski, Esa, Nunes, Baltazar, Rodrigues, Ana Paula, Guiomar, Raquel, Gomes, Victor, Quaresma, Filipa, Vale, Luis, Garcia, Teresa, Bernardo, Teresa, Dias, Liliana, Fonseca, Paula, Amorim, Helena, Rolo, Joao, Pacheco, Helena, Branquinho, Paula, Corte-Real, Rita, Pocas, Jose, Lopes, Paula, Peres, Maria Joao, Ribeiro, Rosa, Duarte, Paula, Pedroso, Ermelinda, Rodrigues, Sara, Silverio, Ana Rita, Pedreira, Diana Gomes, Fonseca, Marta Ferreira, Vince, Adriana, Topić, Antea, Papić, Neven, Mihalić, Jelena Budimir, Novosel, Iva Pem, Petrović, Goranka, Zajec, Martina, Draženović, Vladimir, Hercegh, Eva, Szalai, Balint, Antmann, Katalin, Nagy, Kamilla, Unión Europea, EpiConcept, Institute of Health Carlos III, CIBER de Epidemiología y Salud Pública (CIBERESP), Istituto Superiore de Sanita, University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), CIC Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi-Institut National de la Santé et de la Recherche Médicale (INSERM), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Institut National de la Santé et de la Recherche Médicale (INSERM), National Institute for Health and Welfare [Helsinki], and National Institute for Public Health and the Environment [Bilthoven] (RIVM)

Subjects
Infecções Respiratórias, 0301 basic medicine, Male, Heart disease, Epidemiology, Efetividade da Vacina Antigripal, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Outcome Assessment, Health Care, 80 and over, Influenza A Virus, Medicine, 030212 general & internal medicine, Aged, 80 and over, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, Vaccination, virus diseases, 3. Good health, Europe, Hospitalization, Influenza Vaccines, case control, elderly, hospitalisation, influenza, severe acute respiratory infection, vaccine effectiveness, vaccine-preventable diseases, Vaccine-preventable diseases, Female, Public Health, Seasons, Research Article, Human, medicine.medical_specialty, Influenza vaccine, 030106 microbiology, Aged, Humans, Influenza B virus, Influenza, Human, Logistic Models, Outcome Assessment (Health Care), Sentinel Surveillance, Vaccine Potency, Public Health, Environmental and Occupational Health, Virology, Hospital, 03 medical and health sciences, Diabetes mellitus, Internal medicine, H1N1 Subtype, Vacina Antigripal, Intensive care medicine, business.industry, Environmental and Occupational Health, Cuidados de Saúde, Case-control study, medicine.disease, Influenza, Confidence interval, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, business
Abstract

Members of the I-MOVE+ project - Portugal: Baltazar Nunes, Ana Paula Rodrigues, Raquel Guiomar (Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal), Victor Gomes, Filipa Quaresma, Luis Vale, Teresa Garcia, Teresa Bernardo, Liliana Dias, Paula Fonseca, Helena Amorim, João Rolo, Helena Pacheco, Paula Branquinho, Rita Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon, Portugal),José Poças, Paula Lopes, Maria João Peres, Rosa Ribeiro, Paula Duarte, Ermelinda Pedroso, Sara Rodrigues, Ana Rita Silvério, Diana Gomes Pedreira, Marta Ferreira Fonseca, (Centro Hospitalar de Setúbal, Setúbal, Portugal). We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases. The I-MOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. info:eu-repo/semantics/publishedVersion

Published
2017
Full Text
View/download PDF

11. Diet Optimization in Inflammatory Bowel Disease: Impact on Disease Relapse and Inflammatory Markers. A 1-year Prospective Trial.

Author

Preda CM, Istratescu D, Nitescu M, Manuc T, Manuc M, Stroie T, Tieranu C, Meianu CG, Andrei A, Ciora CA, Louis E, and Diculescu M

Subjects
Humans, Female, Male, Adult, Prospective Studies, Middle Aged, Remission Induction, Leukocyte L1 Antigen Complex analysis, Treatment Outcome, Young Adult, Time Factors, Inflammation Mediators metabolism, Inflammation Mediators blood, Diet, Healthy, Crohn Disease diet therapy, Colitis, Ulcerative diet therapy, Colitis, Ulcerative diagnosis, Biomarkers blood, Recurrence, Feces chemistry
Abstract

Background and Aims: Recent research has shown that Western-style diets have been associated with an increased risk of inflammatory bowel diseases (IBD). Our aim was to examine the link between an anti-inflammatory diet and the maintenance of IBD remission, as well as to assess the potential therapeutic advantages of this dietary approach in preserving IBD remission., Methods: The inclusion and exclusion criteria were applied to a total of 189 individuals with IBD, with 21 individuals not meeting the criteria. Therefore, 168 eligible patients were enrolled in the study and allocated to either an anti-inflammatory diet or a regular diet, based on their personal preference., Results: A cohort of 168 IBD adult patients was recruited for the study: 88 patients with ulcerative colitis and 80 with Crohn's disease. The intervention group received an anti-inflammatory diet consisting of the removal of red and processed meat, fried foods, high-lactose foods, fast food, white bread, sugar, and vegetable oils rich in omega-6 for a period of 1 year. The clinical response was maintained in 80 patients (95.2%) in the intervention group and in 72 patients (85.7%) in the control group (p-value=0.036). Although not statistically significant, fecal calprotectin was higher in the control group than in the intervention group at follow-up., Conclusions: Patients who adhered to an anti-inflammatory diet exhibited a higher rate of maintenance of clinical remission. Furthermore, improvement in inflammation tests was observed in the intervention group, reinforcing the proposition that IBD is a lifestyle-related disease.

Published
2024
Full Text
View/download PDF

12. Impact of Dietary Patterns in Inflammatory Bowel Disease Subtypes Versus Healthy Subjects: a Retrospective Cohort Study.

Author

Preda CM, Istratescu D, Nitescu M, Manuc T, Manuc M, Stroie T, Catrinoiu M, Tieranu C, Meianu CG, Tugui L, Ciora CA, Louis E, and Diculescu M

Abstract

Objectives: Inflammatory bowel diseases (IBD) have been associated with multiple environmental factors, including diet. A dietary pattern characterized by low fiber content, high fat content and high carbohydrate content has been linked to the development of IBD. The objective of the current investigation is to examine the potential link between dietary patterns and the occurrence of IBD and to investigate whether there are any differences in relation to the type of IBD and specific food groups. Material and methods: We conducted an observational retrospective comparative study using three cohorts: 89 Crohn's disease (CD) patients, 40 ulcerative colitis (UC) patients and 64 healthy subjects. All participants underwent structured interviews and were required to complete a questionnaire regarding their dietary habits either prior to the onset of IBD or within the last year for control subjects. Results: A higher proportion of CD patients reported a higher rate of salt intake (71.9% vs . 53.1%, p-value = 0.043), sweetened beverages (38.2% vs . 17.2%, p-value=0.022), processed meat (66.3% vs . 40.6%, p-value=0.007), fatty meat (50.6% vs . 28.1%, p-value=0.021), fried foods (47.2% vs . 9.4%, p-value<0.001) and mayonnaise (21.3% vs . 6.2%, p-value=0.032) and a lower intake of nuts and seeds (20.2% vs . 43.8%, p-value=0.004) and yogurt (23.6% vs . 43.8%, p-value=0.030) compared to healthy subjects. Compared to controls, in the UC group there was a higher consumption of salt (85% vs . 53.1%, p-value=0.003), sweetened beverages (47.5% vs . 17.2%, p-value=0.005), fatty meat (55% vs . 28.1%, p-value=0.025) and fried foods (55% vs . 9.4%, p-value<0.001) and a lower intake of nuts and seeds (10% vs . 43.8%, p-value=0.001). Conclusion: Diet patterns before the onset of the disease are similar in patients with Crohn's disease and patients with ulcerative colitis: increased consumption of sweetened beverages, processed and fatty meat, fried food, salt, store-bought ice cream, and mayonnaise, and decreased intake of seeds, nuts, and yogurt.

Published
2023
Full Text
View/download PDF

13. Plant-Based Dairy Alternatives-A Future Direction to the Milky Way.

Author

Plamada D, Teleky BE, Nemes SA, Mitrea L, Szabo K, Călinoiu LF, Pascuta MS, Varvara RA, Ciont C, Martău GA, Simon E, Barta G, Dulf FV, Vodnar DC, and Nitescu M

Abstract

One significant food group that is part of our daily diet is the dairy group, and both research and industry are actively involved to meet the increasing requirement for plant-based dairy alternatives (PBDAs). The production tendency of PBDAs is growing with a predictable rate of over 18.5% in 2023 from 7.4% at the moment. A multitude of sources can be used for development such as cereals, pseudocereals, legumes, nuts, and seeds to obtain food products such as vegetal milk, cheese, cream, yogurt, butter, and different sweets, such as ice cream, which have nearly similar nutritional profiles to those of animal-origin products. Increased interest in PBDAs is manifested in groups with special dietary needs (e.g., lactose intolerant individuals, pregnant women, newborns, and the elderly) or with pathologies such as metabolic syndromes, dermatological diseases, and arthritis. In spite of the vast range of production perspectives, certain industrial challenges arise during development, such as processing and preservation technologies. This paper aims at providing an overview of the currently available PBDAs based on recent studies selected from the electronic databases PubMed, Web of Science Core Collection, and Scopus. We found 148 publications regarding PBDAs in correlation with their nutritional and technological aspects, together with the implications in terms of health. Therefore, this review focuses on the relationship between plant-based alternatives for dairy products and the human diet, from the raw material to the final products, including the industrial processes and health-related concerns.

Published
2023
Full Text
View/download PDF

14. Role of an Exclusion Diet (Reduced Disaccharides, Saturated Fats, Emulsifiers, Red and Ultraprocessed Meats) in Maintaining the Remission of Chronic Inflammatory Bowel Diseases in Adults.

Author

Nitescu M, Istratescu D, Preda CM, Manuc TE, Louis E, Manuc M, Stroie T, Catrinoiu M, Tieranu CG, Badea LE, Tugui L, Andrei A, and Diculescu MM

Subjects
Animals, Disaccharides, Meat, Crohn Disease therapy, Colitis, Ulcerative therapy, Inflammatory Bowel Diseases therapy
Abstract

Background and Objectives : Inflammatory bowel diseases are a main focus in current research, with diet being an emerging therapeutic line due to its links in both onset and progression. A Western-style diet high in processed foods, food additives, red meat, and animal fat has been linked to a higher risk of developing IBD. The aim of this study was to establish an association between an anti-inflammatory exclusion diet and maintenance of remission in IBD. Also, we assessed the efficacy and safety of this diet compared to a non-dietary group and the possible therapeutic effect of this diet in the maintenance of IBD remission. Materials and Methods : A total of 160 patients with IBD were screened for inclusion, but 21 did not met the inclusion criteria. Thus, 139 patients were assigned to either an exclusion diet or a regular diet according to their choice. Results : Clinical remission after six months was maintained in the exclusion diet arm (100%). In the control arm, four patients had clinically active disease (one patient with UC and three with CD), and 90 patients maintained the clinical remission state (95.7%) ( p -value = 0.157). Regarding biochemical markers, ESR at baseline was higher in the exclusion diet arm: 29 (5-62) versus in the control arm 16 (4-48) ( p -value = 0.019), but six months after, the groups were similar ( p -value = 0.440). Conclusions : Patients who followed an exclusion diet maintained clinical remission more frequently. However, the threshold for statistical significance was not achieved. There was also a trend of improvement in inflammation tests in the intervention group.

Published
2023
Full Text
View/download PDF

15. Diet as an environmental trigger in inflammatory bowel disease: a retrospective comparative study in two European cohorts.

Author

Preda CM, Manuc T, Chifulescu A, Istratescu D, Louis E, Baicus C, Sandra I, Diculescu MM, Reenaers C, van Kemseke C, Nitescu M, Tieranu C, Popescu M, Tugui L, Andrei A, Ciora CA, Gherorghe IS, and Manuc M

Subjects
Cohort Studies, Food, Humans, Retrospective Studies, Risk Factors, Diet, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases etiology
Abstract

Background and Aims: inflammatory bowel disease development has been associated with several environmental factors, among which, diet can play a key role, probably due to a westernized lifestyle. However, its involvement in the pathogenesis of inflammatory bowel disease (IBD) is difficult to demonstrate. The aim of this study was to analyze dietary composition in a Romanian and Belgian population with IBD., Methods: an observational retrospective comparative study was performed using two European cohorts (Romanian and Belgian). The IBD group included 76 Romanian and 53 Belgian patients with an IBD diagnosis, while the control group included a total of 56 healthy people (35 Romanians and 21 Belgians). All subjects were interviewed and asked to fill in a questionnaire regarding diet., Results: in the entire IBD cohort (Romanian + Belgian), a significantly increased consumption of sweets (OR 3.36 [95 % CI 1.6,7]), processed and high fat meat (OR 2.5 [95 % CI 1.4, 4.7], fried food (OR 9.5 [3.8, 23.6]), salt (OR 2.8 [1.5, 5.3]), ice cream (OR 3.25 [1.1, 9.8]), mayonnaise (OR 3.49 [1.1, 10.3]), margarine (OR 5.63 [1.64, 19.33]) and chips/nachos/other snacks (OR 2.3 [0.97, 5.73]) were found compared to the healthy control group. The intake of seeds, nuts (OR 0.26 [0.14, 0.52]) and yoghurt consumption (OR 0.44 [0.23, 0.83]) was lower in the IBD group compared to the control group., Conclusion: a westernized diet with increased consumption of sweets, processed food, high fat meat, fried food, salt, margarine, snacks, ice cream and mayonnaise seems to be a risk factor for IBD in Romanian and Belgian IBD patients. Intake of seeds, nuts and yoghurt may be a protective factor.

Published
2020
Full Text
View/download PDF

16. Environmental Factors in Romanian and Belgian Patients with Inflammatory Bowel Disease - a Retrospective Comparative Study.

Author

Preda CM, Manuc T, Istratescu D, Louis E, Baicus C, Sandra I, Diculescu M, Reenaers C, van Kemseke C, Nitescu M, Tieranu C, Sandu CG, Oprea-Calin G, Tugui L, Viziru S, Ciora CA, Gheorghe LS, and Manuc M

Abstract

Background: Several environmental factors have been associated with onset of inflammatory bowel diseases (IBD): smoking, hygiene, microorganisms, oral contraceptive pills (OCPs), non-steroid anti-inflammatory drugs, antibiotics, appendectomy, diet, breastfeeding, vitamin D, stress and ambient air pollution. The aim of this study was to investigate the prevalence of these factors in a Romanian and Belgian population with IBD. Material and methods: A total of 129 patients with an IBD diagnosis (76 from Romania and 53 from Belgium) participated in an interview and were asked to fill in a questionnaire regarding environmental factors before and after the onset of IBD; 35 Romanian and 21 Belgian healthy individuals constituted the control group. Results: A total of 40 patients with ulcerative colitis (UC) and 89 with Crohn's disease (CD) were included. Gender distribution was 43% males and 57% females. They had a median age of 42 years (range between 19-74 years), a median disease duration of eight years and 79% were in clinical remission. Both Romanian and Belgian IBD patients reported an increased antibiotic consumption before IBD onset compared to controls: 58% vs 10% (p<0.001) and 51% vs 5% (p<0.001), respectively. Belgian IBD patients declared significantly more frequent OCP use (53% vs 9%, p <0.001), they were breastfed in a lower proportion (49% vs 76%, p <0.001) and had experienced a higher level of psychosocial stress (p<0.001). Conclusion: Antibiotic consumption before IBD onset may play a pivotal role in IBD development in both Romanian and Belgian populations. In Belgian patients, OCP consumption, a higher level of psychosocial stress and lack of breastfeeding may also be involved.

Published
2019
Full Text
View/download PDF

18. The Adipokine Profile and the Cardiometabolic Risk in Non-Obese Young Adults

Author

Otelea MR, Streinu-Cercel A, Băicus C, and Nitescu M

Subjects
Adipokines blood, Analysis of Variance, Biomarkers analysis, Biomarkers blood, Body Mass Index, C-Reactive Protein analysis, Cardiovascular Diseases blood, Cardiovascular Diseases physiopathology, Cross-Sectional Studies, Female, Healthy Volunteers statistics & numerical data, Humans, Insulin Resistance, Interleukin-6 analysis, Interleukin-6 blood, Male, Metabolic Diseases blood, Metabolic Diseases physiopathology, Risk Assessment standards, Young Adult, Adipokines analysis, Cardiovascular Diseases classification, Metabolic Diseases classification, Risk Assessment methods
Abstract

Background: Young, non-obese adults are considered at low risk for cardiometabolic diseases, although markers of an unhealthy metabolic state are not uncommon findings in this population. Adipose tissue dysfunction, evaluated by the adipokine profile, significantly influences lipid and glucose metabolism and low-grade systemic inflammation., Aims: To determine the relation between adipose tissue dysfunction and the already confirmed cardiometabolic risk indicators, including the atherogenic index of plasma, lipid accumulation product, homeostatic model assessment of insulin resistance, and the low-grade inflammation markers, namely, interleukin 6 and high-sensitivity C-reactive protein., Study Design: Cross-sectional study., Methods: We recruited 93 non-obese, healthy young adults. Anthropometric, lipid profile, inflammatory markers, and adipokines were measured. An abnormal adipokine profile (high leptin-to-adiponectin ratio) was considered as a marker of a dysfunctional adipose tissue. The correlation between the leptin-to-adiponectin ratio and the anthropometric measurements, atherogenic index of plasma, lipid accumulation product, homeostatic model assessment of insulin resistance, interleukin 6, and high-sensitivity C-reactive protein was determined., Results: We found a direct correlation between the abnormal adipokine profile and the cardiometabolic risk indicators mentioned above, except for the low-grade inflammatory markers. In the regression model derived from our data, the leptin-to-adiponectin ratio was best correlated with the unfavorable plasma lipid profile, as estimated by the atherogenic index of plasma (r=0.097, confidence interval=0.015-0.180, p=0.021). A significantly higher leptin-to-adiponectin ratio was found in the insulin-resistant group (p=0.012) and in the highest lipid accumulation product quartile (p=0.032)., Conclusion: In a non-obese young population, the high rate of leptin-adiponectin may be a good predictor of cardiovascular and metabolic risk assessment.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results